Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

NCT ID: NCT01652872

Last Updated: 2022-09-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 756 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-30
• Study Completion Date: 2017-10-19

Brief Summary

A phase 3, multicenter, randomized, double-blind, parallel group study. Anemic subjects with chronic kidney disease (CKD) and not on dialysis will be randomized 1:1 to 1 of 2 dosing strategies to evaluate the proportion of subjects receiving at least one red blood cell (RBC) transfusion. In the haemoglobin (Hb)-based titration group, darbepoetin alfa doses will be titrated to maintain Hb ≥ 10.0 grams/deciliter (g/dL). In the fixed dose group, subjects will receive a fixed dose of darbepoetin alfa. Treatment group, darbepoetin alfa doses, and protocol specified Hb concentrations will be blinded. Subjects will be followed for approximately 2 years from the date of randomization.

Detailed Description

The study is a phase 3, multicenter, randomized, double-blind, parallel group study designed to describe the benefits and potential risks of a new treatment strategy using a fixed dose of darbepoetin alfa in subjects with CKD and not on dialysis. Anemic subjects without recent use of an erythropoiesis stimulating agent (ESA) will be randomly allocated 1:1 to treatment with a fixed dose of darbepoetin alfa or to treatment with darbepoetin alfa using a Hb-based titration strategy, which has been the conventional dosing strategy. In the Hb-based titration group, darbepoetin alfa doses will be titrated to maintain Hb ≥ 10.0 g/dL. This study aims to estimate the incidence of RBC transfusions (administered as deemed clinically necessary) in each group and the difference in incidence of RBC transfusions between the 2 groups. In addition, multiple aspects, such as cumulative darbepoetin alfa dose, total number of units of transfusions, Hb concentration, Hb-related parameters (eg, Hb variability, excursions, rate of change), and adverse (eg, cardiovascular) events, will also be considered in order to determine a preferred dosing regimen. Treatment group, darbepoetin alfa doses, and protocol specified Hb concentrations will be blinded to the investigator, subjects and study team. Subjects will be followed for approximately 2 years from the date of randomization.

Conditions

Anemia in Chronic Kidney Disease Patients Not on Dialysis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Hb-Based Titration Group

Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.

Group Type: ACTIVE_COMPARATOR

Darbepoetin alfa

Intervention Type: BIOLOGICAL

Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.

Placebo

Intervention Type: OTHER

Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.

Fixed Dose Group

Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was \> 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to \< 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.

Group Type: EXPERIMENTAL

Darbepoetin alfa

Intervention Type: BIOLOGICAL

Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.

Placebo

Intervention Type: OTHER

Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.

Interventions

Darbepoetin alfa

Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.

Intervention Type: BIOLOGICAL

Placebo

Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.

Intervention Type: OTHER

Other Intervention Names

Aranesp

Eligibility Criteria

Inclusion Criteria

• Clinical history of advanced CKD not on dialysis with at least 1 historic estimated glomerular filtration rate (eGFR) < 45.0 mL/mi)/1.73 m2 at least 12 weeks prior to screening
• Not currently receiving dialysis with an eGFR < 45.0 mL/min/1.73m2, per the central laboratory during screening
• Chronic anemia due to renal failure
• Two Hb concentrations < 10.0 g/dL, at least 2 weeks apart during screening using the modified Hb point of care (POC) device
• Iron replete, defined as a transferrin saturation (TSAT) ≥ 20% and a ferritin ≥ 100 ng/mL, per the central laboratory during screening
• Vitamin B12 and folate replete, defined as a vitamin B12 level > 180 pg/mL and a folate concentration > 7 nmol/L, per the central laboratory during screening
• Clinically stable in the opinion of the investigator
• Subject has provided written informed consent

Exclusion Criteria

• Systemic hematologic disease (eg, sickle cell anemia, myelodysplastic syndrome, hematologic malignancy)
• Current or prior malignancy within 5 years of screening, with the exception of non-melanoma skin cancers and cervical intraepithelial neoplasia
• Treatment for any malignancy (eg, radiation, chemotherapy, hormone therapy, or biologics) within 5 years of screening, with the exception of locally excised non-melanoma skin cancer or cervical intraepithelial neoplasia
• Female subject not willing to use highly effective methods of birth control during treatment and for 4 weeks after the end of treatment
• Subject is pregnant or breast feeding, or might become pregnant during the study or within 4 weeks after the end of treatment
• Currently receiving intravenous (IV) antibiotics for treatment of an active infection
• Known Human Immunodeficiency Virus (HIV) positive
• Currently receiving systemic immunosuppressive therapy with the exception of prednis(ol)one ≤ 10 mg per day (or the steroid equivalent)
• History of any organ transplant
• Currently enrolled in another interventional study (eg, studies which require medical device use or drug therapy or with protocol required procedures), or less than 4 weeks since ending another interventional study(s) or receiving investigational agent(s)
• Known neutralizing anti-erythropoietic protein antibodies
• Known sensitivity to any of the products to be administered during dosing
• Previously enrolled in this study
• Not expected to be available for protocol required study visits or procedures to the best of the subject and investigator's knowledge
• Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with all required study procedures
• Occurrence of stroke or myocardial infarction (MI) within 24 weeks of screening
• Receipt of RBC transfusion within 8 weeks of screening
• Occurrence of seizure, clinically relevant active bleeding (eg, gastrointestinal [GI] bleed) or any hospitalization within 8 weeks of screening
• Receipt of any IV iron therapy within 4 weeks of screening
• Changes in oral iron therapy within 4 weeks of screening
• Receipt of ESA therapy within 4 weeks of screening
• Diagnosis or treatment of malignancy, with the exception of non-melanoma skin cancers and cervical intraepithelial neoplasia during screening
• Receipt of ESA therapy, RBC transfusions, IV iron therapy during screening
• Changes in oral iron therapy during screening
• Occurrence of stroke, MI, seizure, clinically relevant active bleeding (eg, GI bleed), any hospitalization or outpatient surgery during screening
• Uncontrolled hypertension during screening. Defined in this study, as a mean systolic blood pressure > 140 mmHg at both screening visits, or a mean systolic blood pressure >/= 160 mmHg at any screening visit, or a mean diastolic blood pressure >/= 90 mmHg at any screening visit.
• Expected or scheduled change in oral iron therapy or receipt of IV iron therapy within 4 weeks after randomization
• Expected or scheduled receipt of a RBC transfusion within 8 weeks after randomization
• Expected or scheduled organ transplant within 24 weeks after randomization
• Expected or scheduled initiation of dialysis within 24 weeks after randomization

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Research Site

Anniston, Alabama, United States

Research Site

Birmingham, Alabama, United States

Research Site

Huntsville, Alabama, United States

Research Site

Mobile, Alabama, United States

Research Site

Mobile, Alabama, United States

Research Site

Montgomery, Alabama, United States

Research Site

Goodyear, Arizona, United States

Research Site

Peoria, Arizona, United States

Research Site

Phoenix, Arizona, United States

Research Site

Phoenix, Arizona, United States

Research Site

Phoenix, Arizona, United States

Research Site

Tempe, Arizona, United States

Research Site

Little Rock, Arkansas, United States

Research Site

Alhambra, California, United States

Research Site

Anaheim, California, United States

Research Site

Azusa, California, United States

Research Site

Bakersfield, California, United States

Research Site

Bakersfield, California, United States

Research Site

Bell Gardens, California, United States

Research Site

Beverly Hills, California, United States

Research Site

Cerritos, California, United States

Research Site

Chula Vista, California, United States

Research Site

Cudahy, California, United States

Research Site

El Centro, California, United States

Research Site

Fountain Valley, California, United States

Research Site

Fullerton, California, United States

Research Site

Garden Grove, California, United States

Research Site

Glendale, California, United States

Research Site

Granada Hills, California, United States

Research Site

Huntington Beach, California, United States

Research Site

Inglewood, California, United States

Research Site

La Jolla, California, United States

Research Site

La Mesa, California, United States

Research Site

Laguna Hills, California, United States

Research Site

Lakewood, California, United States

Research Site

Lancaster, California, United States

Research Site

Lomita, California, United States

Research Site

Long Beach, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Lynwood, California, United States

Research Site

Mission Hills, California, United States

Research Site

Modesto, California, United States

Research Site

Northridge, California, United States

Research Site

Northridge, California, United States

Research Site

Orange, California, United States

Research Site

Rancho Mirage, California, United States

Research Site

Redondo Beach, California, United States

Research Site

Riverside, California, United States

Research Site

Sacramento, California, United States

Research Site

San Dimas, California, United States

Research Site

Whittier, California, United States

Research Site

Whittier, California, United States

Research Site

Yuba City, California, United States

Research Site

Arvada, Colorado, United States

Research Site

Westminster, Colorado, United States

Research Site

Middlebury, Connecticut, United States

Research Site

New Haven, Connecticut, United States

Research Site

North Haven, Connecticut, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Boynton Beach, Florida, United States

Research Site

Coral Springs, Florida, United States

Research Site

Daytona Beach, Florida, United States

Research Site

DeLand, Florida, United States

Research Site

Fort Lauderdale, Florida, United States

Research Site

Hollywood, Florida, United States

Research Site

Hudson, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

Jacksonville Beach, Florida, United States

Research Site

Lauderdale Lakes, Florida, United States

Research Site

Melbourne, Florida, United States

Research Site

Melbourne, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami Beach, Florida, United States

Research Site

Naples, Florida, United States

Research Site

New Port Richey, Florida, United States

Research Site

New Port Richey, Florida, United States

Research Site

Orlando, Florida, United States

Research Site

Pembroke Pines, Florida, United States

Research Site

Port Charlotte, Florida, United States

Research Site

Summerfield, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Augusta, Georgia, United States

Research Site

Canton, Georgia, United States

Research Site

Macon, Georgia, United States

Research Site

Newnan, Georgia, United States

Research Site

Honolulu, Hawaii, United States

Research Site

Meridian, Idaho, United States

Research Site

Chicago, Illinois, United States

Research Site

Chicago, Illinois, United States

Research Site

Chicago, Illinois, United States

Research Site

Evanston, Illinois, United States

Research Site

Peoria, Illinois, United States

Research Site

Quincy, Illinois, United States

Research Site

Columbus, Indiana, United States

Research Site

Michigan City, Indiana, United States

Research Site

Ames, Iowa, United States

Research Site

Kansas City, Kansas, United States

Research Site

Wichita, Kansas, United States

Research Site

Lexington, Kentucky, United States

Research Site

Paducah, Kentucky, United States

Research Site

Baton Rouge, Louisiana, United States

Research Site

Lafayette, Louisiana, United States

Research Site

Metairie, Louisiana, United States

Research Site

Natchitoches, Louisiana, United States

Research Site

New Orleans, Louisiana, United States

Research Site

Ruston, Louisiana, United States

Research Site

Shreveport, Louisiana, United States

Research Site

Rockport, Maine, United States

Research Site

Bethesda, Maryland, United States

Research Site

Oxon Hill, Maryland, United States

Research Site

Framingham, Massachusetts, United States

Research Site

Plymouth, Massachusetts, United States

Research Site

Springfield, Massachusetts, United States

Research Site

Flint, Michigan, United States

Research Site

Grand Rapids, Michigan, United States

Research Site

Kalamazoo, Michigan, United States

Research Site

Midland, Michigan, United States

Research Site

Pontiac, Michigan, United States

Research Site

Royal Oak, Michigan, United States

Research Site

Southgate, Michigan, United States

Research Site

Columbus, Mississippi, United States

Research Site

Gulfport, Mississippi, United States

Research Site

City of Saint Peters, Missouri, United States

Research Site

Kansas City, Missouri, United States

Research Site

Kansas City, Missouri, United States

Research Site

Lincoln, Nebraska, United States

Research Site

North Platte, Nebraska, United States

Research Site

Henderson, Nevada, United States

Research Site

Las Vegas, Nevada, United States

Research Site

Eatontown, New Jersey, United States

Research Site

Livingston, New Jersey, United States

Research Site

Toms River, New Jersey, United States

Research Site

Voorhees Township, New Jersey, United States

Research Site

Albany, New York, United States

Research Site

Brooklyn, New York, United States

Research Site

Buffalo, New York, United States

Research Site

Flushing, New York, United States

Research Site

Great Neck, New York, United States

Research Site

Mineola, New York, United States

Research Site

New York, New York, United States

Research Site

Orchard Park, New York, United States

Research Site

Rochester, New York, United States

Research Site

Rosedale, New York, United States

Research Site

The Bronx, New York, United States

Research Site

Asheville, North Carolina, United States

Research Site

Chapel Hill, North Carolina, United States

Research Site

Durham, North Carolina, United States

Research Site

Greensboro, North Carolina, United States

Research Site

Greenville, North Carolina, United States

Research Site

Kinston, North Carolina, United States

Research Site

Mooresville, North Carolina, United States

Research Site

New Bern, North Carolina, United States

Research Site

Statesville, North Carolina, United States

Research Site

Wilmington, North Carolina, United States

Research Site

Winston-Salem, North Carolina, United States

Research Site

Winston-Salem, North Carolina, United States

Research Site

Fargo, North Dakota, United States

Research Site

Fargo, North Dakota, United States

Research Site

Grand Forks, North Dakota, United States

Research Site

Columbus, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Marion, Ohio, United States

Research Site

Poland, Ohio, United States

Research Site

Toledo, Ohio, United States

Research Site

Willoughby Hills, Ohio, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Tulsa, Oklahoma, United States

Research Site

Portland, Oregon, United States

Research Site

Portland, Oregon, United States

Research Site

Roseburg, Oregon, United States

Research Site

Beaver, Pennsylvania, United States

Research Site

Bethlehem, Pennsylvania, United States

Research Site

Doylestown, Pennsylvania, United States

Research Site

Duncansville, Pennsylvania, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Anderson, South Carolina, United States

Research Site

Columbia, South Carolina, United States

Research Site

Greenville, South Carolina, United States

Research Site

Orangeburg, South Carolina, United States

Research Site

Bristol, Tennessee, United States

Research Site

Columbia, Tennessee, United States

Research Site

Dyersburg, Tennessee, United States

Research Site

Franklin, Tennessee, United States

Research Site

Jackson, Tennessee, United States

Research Site

Kingsport, Tennessee, United States

Research Site

Knoxville, Tennessee, United States

Research Site

Memphis, Tennessee, United States

Research Site

Arlington, Texas, United States

Research Site

Austin, Texas, United States

Research Site

Austin, Texas, United States

Research Site

Austin, Texas, United States

Research Site

Corsicana, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

Edinburg, Texas, United States

Research Site

El Paso, Texas, United States

Research Site

Fort Worth, Texas, United States

Research Site

Frisco, Texas, United States

Research Site

Greenville, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Lubbock, Texas, United States

Research Site

Lufkin, Texas, United States

Research Site

McAllen, Texas, United States

Research Site

McKinney, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Temple, Texas, United States

Research Site

Burlington, Vermont, United States

Research Site

Alexandria, Virginia, United States

Research Site

Chesapeake, Virginia, United States

Research Site

Fairfax, Virginia, United States

Research Site

Fairfax, Virginia, United States

Research Site

Hampton, Virginia, United States

Research Site

Manassas, Virginia, United States

Research Site

Mechanicsville, Virginia, United States

Research Site

Norfolk, Virginia, United States

Research Site

Richmond, Virginia, United States

Research Site

Richmond, Virginia, United States

Research Site

Richmond, Virginia, United States

Research Site

Silverdale, Washington, United States

Research Site

Bluefield, West Virginia, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Caguas, , Puerto Rico

Research Site

Ponce, , Puerto Rico

Research Site

Ponce, , Puerto Rico

Research Site

Rio Piedras, , Puerto Rico

Research Site

San Juan, , Puerto Rico

Research Site

San Juan, , Puerto Rico

Countries

United States; Puerto Rico

References

Toto R, Petersen J, Berns JS, Lewis EF, Tran Q, Weir MR. A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. J Am Soc Nephrol. 2021 Feb;32(2):469-478. doi: 10.1681/ASN.2020050556. Epub 2020 Dec 7.

Reference Type: BACKGROUND

PMID: 33288629 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

20110226

Identifier Type: -

Identifier Source: org_study_id